Aripiprazole Lauroxil and Sunitinib Malate
Determining the interaction of Aripiprazole Lauroxil and Sunitinib Malate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using ARIPiprazole together with SUNItinib can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval. In clinical trials with aripiprazole involving patients with schizophrenia or bipolar mania, the incidence of QT prolongation was comparable to placebo. In postmarketing experience, QT prolongation, sudden death, torsade de pointes, ventricular tachycardia, arrhythmia, and cardiopulmonary arrest have been reported. However, these events were very rare or isolated, and many of the patients had preexisting cardiovascular disease, were on concomitant medications known to prolong the QT interval, had risk factors for QT prolongation, took an overdose of aripiprazole, and/or were morbidly obese. On the contrary, most data available in the medical literature suggest that aripiprazole either has no effect on the QT interval, or it may even cause a slight shortening of the QT interval within the dosage range of 10 to 30 mg/day.
MANAGEMENT: Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation. ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Keck PE Jr, Marcus R, Tourkodimitris S, et al. "A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania." Am J Psychiatry 160 (2003): 1651-8
- Kane JM, Carson WH, Saha AR, et al. "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder." J Clin Psychiatry 63 (2002): 763-71
- Goodnick PJ, Jerry J, Parra F "Psychotropic drugs and the ECG: focus on the QTc interval." Expert Opin Pharmacother 3 (2002): 479-98
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Nelson S, Leung JG "Torsades de Pointes After Administration of Low-Dose Aripiprazole (February)." Ann Pharmacother (2013):
- Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study." J Clin Psychiatry 64 (2003): 1048-56
Generic Name: aripiprazole
Brand name: Abilify, Abilify Discmelt, Abilify Maintena, Aristada, Abilify MyCite, Aristada Initio
Synonyms: Aripiprazole, ARIPiprazole
Generic Name: sunitinib
Brand name: Sutent
Synonyms: Sunitinib, SUNItinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aripiprazole Lauroxil-Sunkist Vitamin C
- Aripiprazole Lauroxil-Sunmark 12 Hour Allergy Relief
- Aripiprazole Lauroxil-Sunmark Acid Reducer
- Aripiprazole Lauroxil-Sunmark Acid Reducer Maximum Strength
- Aripiprazole Lauroxil-Sunmark Acid Reducer Ranitidine
- Aripiprazole Lauroxil-Sunmark All Day Allergy-D
- Sunitinib Malate-Aripiprazole lauroxil Intramuscular
- Sunitinib Malate-Aripiprazole ODT
- Sunitinib Malate-Aripiprazole Oral Solution
- Sunitinib Malate-Aripiprazole Orally Disintegrating Tablets
- Sunitinib Malate-Aripiprazole Tablets
- Sunitinib Malate-Aripiprazole Tablets with Sensor